1STBIO and LigaChemBio Announce Strategic R&D and Licensing Option Agreement
Expanded collaboration leverages complementary expertise to unlock next-generation oncology therapeutics
Focus on breakthrough ADC payloads and immuno-oncology candidates with out-licensing potential
YONGIN, South Korea, April 22, 2025 — 1ST Biotherapeutics, Inc. ('1STBIO') and LigaChem Biosciences (KOSDAQ: 141080KS, 'LigaChemBio') announced that they have entered into a strategic partnership and licensing option agreement to co-develop novel payloads for antibody-drug conjugates (ADCs) as well as small molecule immuno-oncology therapies.
Under the terms of the agreement, the two companies will collaborate to identify and develop 2–4 novel drug candidates over the next three years, including next-generation ADC payloads and small molecule oncology assets. LigaChemBio will provide initial funding for joint R&D activities and retain exclusive licensing options for the resulting candidates. Upon exercising the option, LigaChemBio will have the right to out-license assets to third parties and share revenues with 1STBIO. Further financial details were not disclosed.
The agreement builds on an ongoing joint research project that began in December 2024. Recognizing a strong fit and potential synergies between the teams, LigaChem Bio opted to expand the alliance. The partnership is expected to overcome limitations of current ADC payloads and unlock first-in-class or best-in-class oncology programs.
'1STBIO's cutting-edge R&D capabilities are at the core of this collaboration,' said Jamie Jae Eun Kim, CEO of 1ST Biotherapeutics. 'By combining our strengths, we aim to not only advance ADC payload innovation, but also to drive meaningful breakthroughs in small molecule immuno-oncology. This expanded partnership reflects our commitment to building sustainable, innovation-driven biotech alliances.'
'We are pleased to collaborate with 1STBIO, a company with strong capabilities in small molecule drug discovery and oncology,' said Yong-Zu Kim, CEO of LigaChemBio. 'Beyond this partnership, we will continue to pursue open innovation with biotech companies worldwide to deliver transformative therapies to patients.'
###
About 1ST Biotherapeutics, Inc.
1ST Biotherapeutics is a science-driven biopharmaceutical company focused on the development of breakthrough therapies in immuno-oncology, neurodegenerative diseases, and rare diseases. Founded in 2016, the Company has developed a pipeline of investigational drugs aimed at addressing critical unmet medical needs. The Company is headquartered in Yongin, South Korea. For more information, visit http://www.1stbio.com
About LigaChem Biosciences
LigaChem Biosciences (LCB, KOSDAQ: 141080) is a clinical-stage biopharmaceutical company focusing on the development of next-generation novel therapeutics utilizing its proprietary medicinal drug discovery technology and ADC platform technology ConjuAll™. Since its foundation in 2006, LCB has focused on the research and development of antibody-drug conjugates (ADCs), anticancer therapeutics based on proprietary platform technologies.
For more information, please visit www.ligachembio.com.
Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts, including statements regarding 1ST Biotherapeutics, Inc. ('1STBIO')'s research and development plans, the potential of its LRRK2-targeting candidates, its participation in the LITE program, and the expected impact of such participation on Parkinson's disease treatment development, are forward-looking statements. These statements reflect 1STBIO's current expectations and projections about future events and are subject to various risks, uncertainties, and assumptions. Actual results may differ materially and adversely from those expressed or implied in these statements due to a variety of factors. 1STBIO undertakes no obligation to update or revise any forward-looking statements to reflect events or circumstances after the date of this press release, except as required by applicable law.
Contact 1ST Biotherapeutics, Inc.
[email protected]
Tel. +82 31 8023 5332
Media InquiriesakampionDr. Ludger Wess / Ines-Regina Buth Managing Partners
[email protected] Tel. +49 40 88 16 59 64 /
Tel. +49 30 23 63 27 68
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 hours ago
- Business Wire
Hamilton ETFs Plans to Launch Canada's First 0DTE ETFs
TORONTO--(BUSINESS WIRE)--Hamilton Capital Partners Inc. ("Hamilton ETFs") is pleased to announce that it has filed a preliminary prospectus with the Canadian securities regulators for a new suite of exchange traded funds ('ETFs'), the DayMAX™ ETFs, Canada's first suite of ETFs to utilize zero days to expiration ('0DTE') (i.e. ultra-short-term) options to provide attractive income. Subject to receipt of all necessary regulatory approvals, the DayMAX™ suite of ETFs (or the '0DTE ETFs') will seek to provide unitholders with attractive income through the use of 0DTE options and modest leverage of 25%. Hamilton ETFs will apply for the conditional listing approval of the 0DTE ETFs on the Toronto Stock Exchange (the 'TSX'). Hamilton ETFs expects the 0DTE ETFs to be listed under the ticker symbols noted below. Hamilton DayMAX™ Suite of ETFs – Canada's First 0DTE ETFs ETF Name Proposed Ticker Units Investment Objective Hamilton Enhanced Canadian Equity DayMAX™ ETF CDAY Class E Units The investment objective of CDAY is to deliver attractive income while providing exposure primarily, but not exclusively, to Canadian equities. To supplement income earned from its holdings, CDAY employs an actively managed, primarily ultra-short-term, option strategy on its North American equity exposure. Hamilton Enhanced U.S. Equity DayMAX™ ETF SDAY Class E Units The investment objective of SDAY is to deliver attractive income while providing exposure primarily to U.S. equities. To supplement income earned from its holdings, SDAY employs an actively managed, primarily ultra-short-term, option strategy. Hamilton Enhanced Technology DayMAX™ ETF QDAY Class E Units The investment objective of QDAY is to deliver attractive income while providing exposure primarily to U.S. technology-focused equities. To supplement income earned from its holdings, QDAY employs an actively managed, primarily ultra-short-term, option strategy. Expand 'We're proud to introduce Canada's first suite of ETFs using 0DTE options with our DayMAX™ lineup – CDAY, SDAY, and QDAY – giving income-focused investors a new way to generate higher and more frequent cash flow. By writing daily call options and employing modest 25% leverage, DayMAX™ ETFs aim to deliver attractive premium income, broad equity exposure, and the potential to benefit from overnight market gains,' said Pat Sommerville, Senior Partner and Co-President at Hamilton ETFs. The preliminary prospectus dated June 3, 2025, containing important information relating to the 0DTE ETFs, has been filed with the securities commissions or similar authorities in each of the provinces and territories of Canada. A copy of the preliminary prospectus is available on Prospective investors cannot buy units of the 0DTE ETFs until the relevant securities commissions or similar authorities issue receipts for the final prospectus of the 0DTE ETFs and the 0DTE ETFs begin trading on the TSX. For more information on CDAY, SDAY, and QDAY and the rest of Hamilton ETFs' innovative lineup of ETFs, please visit About Hamilton Capital Partners Inc. (Hamilton ETFs) With over $8 billion in assets under management, Hamilton ETFs is one of Canada's fastest-growing ETF providers, offering a suite of innovative exchange traded funds (ETFs) designed to maximize income and growth from trusted sectors in Canada and across the globe. The firm is also an active commentator on the global financial services sector and Canadian banks; the firm's most recent Insights can be found at Commissions, management fees and expenses all may be associated with an investment in exchange traded funds (ETFs). Please read the prospectus before investing. ETFs are not guaranteed, their values change frequently and past performance may not be repeated. Certain statements contained in this news release constitute forward-looking information within the meaning of Canadian securities laws. Forward-looking information may relate to a future outlook and anticipated distributions, events or results and may include statements regarding future financial performance. In some cases, forward-looking information can be identified by terms such as "may", "will", "should", "expect", "anticipate", "believe", "intend" or other similar expressions concerning matters that are not historical facts. Actual results may vary from such forward-looking information. Hamilton ETFs undertakes no obligation to update publicly or otherwise revise any forward-looking statement whether as a result of new information, future events or other such factors which affect this information, except as required by law. This material is for informational purposes only. This material is not intended to be relied upon as research, investment, or tax advice and is not an implied or express recommendation, offer or solicitation to buy or sell any security or to adopt any particular investment or portfolio strategy. Any views and opinions expressed do not take into account the particular investment objectives, needs, restrictions and circumstances of a specific investor and, thus, should not be used as the basis of any specific investment recommendation. Investors should consult a financial and/or tax advisor for financial and/or tax information applicable to their specific situation.
Yahoo
2 hours ago
- Yahoo
/C O R R E C T I O N -- Tricoci Salon and Spa/
In the news release, Tricoci Unveils TricociSkin™ Facial and First-Ever Professional-Grade Skincare Line Built on Decades of Professional Expertise, issued 04-Jun-2025 by Tricoci Salon and Spa over PR Newswire, we are advised by the company of an update to the release. The complete, corrected release follows: Nearly 50 Years of Skin Expertise Brought to Life in Tricoci's First Skincare Collection CHICAGO, June 4, 2025 /PRNewswire/ -- Tricoci Salon & Spa, a leader in luxury beauty and wellness for nearly five decades, proudly introduces the TricociSkin™ Facial a newly developed service designed by its esthetician team, launched in tandem with Tricoci Skincare, the brand's first professional-grade skincare line. This dual debut brings Tricoci's legacy of expert service into the skincare category, offering a complete, results-driven approach to long-term skin health and visible improvement. Introducing the TricociSkin™ FacialThe TricociSkin™ Facial is a 60-minute, fully personalized treatment developed by Tricoci's licensed estheticians to deliver real results through expert hands-on care. Featuring a signature five-point technique, the service is designed to enhance product absorption, support skin function, and create lasting improvements in tone, texture, and radiance. "This is an essential skin treatment, not a trend," says Jamee Taylor, Senior Vice President of Service & Education. "It's results-driven and carefully crafted by our estheticians to reflect the way real clients want to feel and look – confident, cared for, and in control of their skin." Daily Essentials for Healthy SkinTo extend the benefits of the facial beyond the treatment room, Tricoci introduces Tricoci Skincare, a curated line of 11 daily-use products designed to address a wide range of skin needs. Formulated with clinical-grade ingredients, the collection blends performance and simplicity, empowering clients to maintain professional-level results at home. "We've spent decades building trust through our services. With Tricoci Skincare, we're delivering that same level of care and effectiveness in every product," says Teri-Ann Marchigiani, Vice President of Product Development. "These formulas were developed with our estheticians to meet real client needs – clean, effective, and designed to deliver." Each product is thoughtfully crafted to integrate into a personalized regimen, providing visible results and supporting healthy skin between services. Beauty Innovation from WithinThis marks the third brand launch to emerge from Tricoci's internal Beauty CPG innovation hub, following the success of Tricoci Collection (salon-grade haircare) and Nutrire (clinical-luxury scalp and strand care). Every product is developed in close collaboration with the professionals who use them daily, blending deep service expertise with high-performance formulations to create brands that are both authentic and effective. "This is what sets us apart," says Taylor. "Our products come directly from our service floor – from the professionals who understand skin, hair, and client needs best. With every new brand, we're elevating what it means to innovate from within."AvailabilityThe TricociSkin™ Facial and skincare line will be available at all Tricoci Salon & Spa locations beginning June 3, 2025. To book an appointment or explore the full product line, visit About Tricoci Salon & SpaTricoci Salon & Spa is the leading destination for luxury beauty and wellness services, with 13 locations across Chicago and its suburbs. Known for its modern, elevated approach to self-care, Tricoci offers a full range of salon and spa services, including expert haircuts, dimensional color, extensions, skincare, massage, nails, and waxing. Every service is delivered by highly trained professionals in a luxurious, welcoming environment. With a focus on innovation, education, and personalized care, Tricoci empowers clients to look and feel their best with every visit. Media Contact:Kelly Kalmbachkelly@ View original content to download multimedia: SOURCE Tricoci Salon and Spa Sign in to access your portfolio
Business Wire
3 hours ago
- Business Wire
UiPath to Host Product Webinar Showcasing Agentic Automation Capabilities
NEW YORK--(BUSINESS WIRE)--UiPath, Inc. (NYSE: PATH), a global leader in agentic automation, today announced that it will host a live webinar to showcase its agentic automation capabilities. The webinar will be hosted live on June 18, 2025, from 11:00 am to 12:00 pm ET. The event will feature a fireside chat, product demonstration, and Q&A session highlighting the company's latest innovations in agentic automation. UiPath Fireside Chat and Product Demonstration with Daniel Dines and Graham Sheldon When: Wednesday, June 18, 2025 Time: 11:00 am ET Location: Virtual (Register Here) The presentation will be available via live webcast and archived replay on the Investor Relations section of the Company's website ( About UiPath UiPath (NYSE: PATH) is a global leader in agentic automation, empowering enterprises to harness the full potential of AI agents to autonomously execute and optimize complex business processes. The UiPath Platform™ uniquely combines controlled agency, developer flexibility, and seamless integration to help organizations scale agentic automation safely and confidently. Committed to security, governance, and interoperability, UiPath supports enterprises as they transition into a future where automation delivers on the full potential of AI to transform industries. For more information, visit
